Top

Published in:

01-03-2016 | Original Article

Genetic variants in the ITGB6 gene is associated with the risk of radiation pneumonitis in lung cancer patients treated with thoracic radiation therapy

Authors: Minxiao Yi, Yang Tang, Bo Liu, Qianxia Li, Xiao Zhou, Shiying Yu, Shengling Fu, Yixin Cai, Xianglin Yuan

Published in: Tumor Biology | Issue 3/2016

Abstract

The αvβ6 integrin is a cell surface adhesion molecule that plays critical roles in the injury and inflammation processes. We hypothesized that polymorphisms in αvβ6 integrin genes (ITGAV and ITGB6) might be associated with the risk of radiation pneumonitis (RP) in lung cancer patients treated with thoracic radiation. We genotyped three potentially functional αvβ6 integrin single-nucleotide polymorphisms (rs1839123 and rs4129787 in ITGAV, and rs4665162 in ITGB6) and found that the genotypes of rs4665162 single-nucleotide polymorphisms were predictors of RP development (for grade ≥2 RP, HR = 1.505, 95 % CI 1.069–2.119, P = 0.019; for grade ≥3 RP, HR = 3.006, 95 % CI 1.431–6.313, P = 0.004). Our results showed that AG/GG genotypes of ITGB6 rs4665162 gene were associated with a higher risk of RP in patients with lung cancer receiving radiotherapy and thus may serve as a reliable predictor of RP. Further studies will be needed to confirm these findings.

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. United States.CrossRefPubMed

Cannon DM, Mehta MP, Adkison JB, Khuntia D, Traynor AM, Tome WA, et al. Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer. J Clin Oncol. 2013;31:4343–8. United States.CrossRefPubMedPubMedCentral

Yin M, Liao Z, Liu Z, Wang L-E, O’Reilly M, Gomez D, et al. Genetic variants of the nonhomologous end joining gene LIG4 and severe radiation pneumonitis in nonsmall cell lung cancer patients treated with definitive radiotherapy. Cancer. 2012;118:528–35. United States.CrossRefPubMed

Provatopoulou X, Athanasiou E, Gounaris A. Predictive markers of radiation pneumonitis. Anticancer Res. 2008;28:2421–32. Greece.PubMed

Pu X, Wang L, Chang JY, Hildebrandt MAT, Ye Y, Lu C, et al. Inflammation-related genetic variants predict toxicity following definitive radiotherapy for lung cancer. Clin Pharmacol Ther. 2014;96:609–15. United States.CrossRefPubMedPubMedCentral

Mak RH, Alexander BM, Asomaning K, Heist RS, Liu C, Su L, et al. A single-nucleotide polymorphism in the methylene tetrahydrofolate reductase (MTHFR) gene is associated with risk of radiation pneumonitis in lung cancer patients treated with thoracic radiation therapy. Cancer. 2012;118:3654–65. United States.CrossRefPubMed

Yuan X, Liao Z, Liu Z, Wang L-E, Tucker SL, Mao L, et al. Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. J Clin Oncol. 2009;27:3370–8. United States.CrossRefPubMedPubMedCentral

Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell. 1999;96:319–28. United States.CrossRefPubMed

Sugimoto K, Kudo M, Sundaram A, Ren X, Huang K, Bernstein X, et al. The alphavbeta6 integrin modulates airway hyperresponsiveness in mice by regulating intraepithelial mast cells. J Clin Invest. 2012;122:748–58. United States.CrossRefPubMedPubMedCentral

10.

Moore KM, Thomas GJ, Duffy SW, Warwick J, Gabe R, Chou P, et al. Therapeutic targeting of integrin alphavbeta6 in breast cancer. J Natl Cancer Inst. 2014;106:pii: dju169. United States.CrossRef

11.

Pi L, Robinson PM, Jorgensen M, Oh S-H, Brown AR, Weinreb PH, et al. Connective tissue growth factor and integrin alphavbeta6: a new pair of regulators critical for ductular reaction and biliary fibrosis in mice. Hepatology. 2015;61:678–91. United States.CrossRefPubMedPubMedCentral

12.

Vujaskovic Z, Thrasher BA, Jackson IL, Brizel MB, Brizel DM. Radioprotective effects of amifostine on acute and chronic esophageal injury in rodents. Int J Radiat Oncol Biol Phys. 2007;69:534–40. United States.CrossRefPubMed

13.

Breuss JM, Gallo J, DeLisser HM, Klimanskaya IV, Folkesson HG, Pittet JF, et al. Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. J Cell Sci. 1995;108(Pt 6):2241–51. England.PubMed

14.

Weinacker A, Ferrando R, Elliott M, Hogg J, Balmes J, Sheppard D. Distribution of integrins alpha v beta 6 and alpha 9 beta 1 and their known ligands, fibronectin and tenascin, in human airways. Am J Respir Cell Mol Biol. 1995;12:547–56. United States.CrossRefPubMed

15.

Puthawala K, Hadjiangelis N, Jacoby SC, Bayongan E, Zhao Z, Yang Z, et al. Inhibition of integrin alpha(v)beta6, an activator of latent transforming growth factor-beta, prevents radiation-induced lung fibrosis. Am J Respir Crit Care Med. 2008;177:82–90. United States.CrossRefPubMed

16.

Shakiba E, Tavilani H, Goodarzi MT, Kiani A, Pourmotabbed T, Vaisi-Raygani A. The ITGAV-rs3911238 polymorphism is associated with disease activity in rheumatoid arthritis. Iran J Allergy Asthma Immunol. 2014;13:356–63. Iran

17.

Lee SK, Kim M-H, Cheong JY, Cho SW, Yang S-J, Kwack K. Integrin alpha V polymorphisms and haplotypes in a Korean population are associated with susceptibility to chronic hepatitis and hepatocellular carcinoma. Liver Int. 2009;29:187–95. England.CrossRefPubMed

18.

Qi L, Cornelis MC, Kraft P, Stanya KJ, Linda Kao WH, Pankow JS, et al. Genetic variants at 2q24 are associated with susceptibility to type 2 diabetes. Hum Mol Genet. 2010;19:2706–15. England.CrossRefPubMedPubMedCentral

19.

Poulter JA, Brookes SJ, Shore RC, Smith CEL, Abi Farraj L, Kirkham J, et al. A missense mutation in ITGB6 causes pitted hypomineralized amelogenesis imperfecta. Hum Mol Genet. 2014;23:2189–97. England.CrossRefPubMed

20.

Van Meerbeeck JP, Fennell DA, De Ruysscher DKM. Small-cell lung cancer. Lancet. 2011;378:1741–55. (London, England). England.CrossRefPubMed

21.

Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG, et al. Non-small-cell lung cancer. Lancet. 2011;378:1727–40. (London, England). England.CrossRefPubMed

22.

Schallenkamp JM, Miller RC, Brinkmann DH, Foote T, Garces YI. Incidence of radiation pneumonitis after thoracic irradiation: dose-volume correlates. Int J Radiat Oncol Biol Phys. 2007;67:410–6. United States.CrossRefPubMed

23.

Kong F-MS, Wang S. Nondosimetric risk factors for radiation-induced lung toxicity. Semin Radiat Oncol. 2015;25:100–9. United States.CrossRefPubMed

24.

Chan C, Lang S, Rowbottom C, Guckenberger M, Faivre-Finn C. Intensity-modulated radiotherapy for lung cancer: current status and future developments. J Thorac Oncol. 2014;9:1598–608. United States.CrossRefPubMed

25.

Shi M, Zhu J, Wang R, Chen X, Mi L, Walz T, et al. Latent TGF-beta structure and activation. Nature. 2011;474:343–9. England.CrossRefPubMedPubMedCentral

26.

Park J, Ryu S-H, Choi EK, Ahn SD, Park E, Choi K-C, et al. SKI2162, an inhibitor of the TGF-beta type I receptor (ALK5), inhibits radiation-induced fibrosis in mice. Oncotarget. 2015;6:4171–9. United States.CrossRefPubMedPubMedCentral

27.

Li J, Mu S, Mu L, Zhang X, Pang R, Gao S. Transforming growth factor-beta-1 is a serum biomarker of radiation-induced pneumonitis in esophageal cancer patients treated with thoracic radiotherapy: preliminary results of a prospective study. Onco Targets Ther. 2015;8:1129–36. New Zealand.CrossRefPubMedPubMedCentral

28.

Niu X, Li H, Chen Z, Liu Y, Kan M, Zhou D, et al. A study of ethnic differences in TGFbeta1 gene polymorphisms and effects on the risk of radiation pneumonitis in non-small-cell lung cancer. J Thorac Oncol. 2012;7:1668–75. United States.CrossRefPubMed

29.

Alsbeih G, Al-Harbi N, Al-Hadyan K, El-Sebaie M, Al-Rajhi N. Association between normal tissue complications after radiotherapy and polymorphic variations in TGFB1 and XRCC1 genes. Radiat Res. 2010;173:505–11. United States.CrossRefPubMed

30.

Zhang L, Yang M, Bi N, Ji W, Wu C, Tan W, et al. Association of TGF-beta1 and XPD polymorphisms with severe acute radiation-induced esophageal toxicity in locally advanced lung cancer patients treated with radiotherapy. Radiother Oncol. 2010;97:19–25. Ireland.CrossRefPubMed

31.

Henderson NC, Arnold TD, Katamura Y, Giacomini MM, Rodriguez JD, McCarty JH, et al. Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med. 2013;19:1617–24. United States.CrossRefPubMed

Title: Genetic variants in the ITGB6 gene is associated with the risk of radiation pneumonitis in lung cancer patients treated with thoracic radiation therapy
Authors: Minxiao Yi
Yang Tang
Bo Liu
Qianxia Li
Xiao Zhou
Shiying Yu
Shengling Fu
Yixin Cai
Xianglin Yuan
Publication date: 01-03-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 3/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-4171-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2016

ZNRF3 contributes to the growth of lung carcinoma via inhibiting Wnt/β-catenin pathway and is regulated by miR-93

The role of MALAT1/miR-1/slug axis on radioresistance in nasopharyngeal carcinoma

Leu/Val SNP polymorphism of CYP1B1 and risk of uterine leiomyoma in a Black population

St Gallen molecular subtypes in feline mammary carcinoma and paired metastases—disease progression and clinical implications from a 3-year follow-up study

The roles of parafibromin expression in ovarian epithelial carcinomas: a marker for differentiation and prognosis and a target for gene therapy

Maspin mediates the gemcitabine sensitivity of hormone-independent prostate cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer